Edwards Lifesciences (EW) gains on buying CardiAQ

Edwards Lifesciences EW shares hiked 3.7% to $152.54. The company said it is buying CardiAQ Valve Technologies Inc., a privately-held developer of a transcatheter mitral-valve replacement system, for up to $400 million, including $350 million in cash at closing. Share volume was 99,000, compared to an all-day average of 246,000